Invention Grant
- Patent Title: Treatment of cancer using a CD33 chimeric antigen receptor
-
Application No.: US14805236Application Date: 2015-07-21
-
Publication No.: US09777061B2Publication Date: 2017-10-03
- Inventor: Hilmar Erhard Ebersbach , Thomas Huber , Julia Jascur , Celeste Richardson , Reshma Singh , Huijuan Song , Qilong Wu , Jiquan Zhang
- Applicant: Novartis AG , The Trustees of the University of Pennsylvania
- Applicant Address: CH Basel US PA Philadelphia
- Assignee: Novartis AG,The Trustees of the University of Pennsylvania
- Current Assignee: Novartis AG,The Trustees of the University of Pennsylvania
- Current Assignee Address: CH Basel US PA Philadelphia
- Agency: Lando & Anastasi, LLP
- Priority: WOPCT/CN2014/082589 20140721; WOPCT/CN2014/090504 20141106
- Main IPC: C12N5/071
- IPC: C12N5/071 ; C12N5/16 ; C07K16/28 ; C07K14/705 ; A61K39/395 ; A61K31/436 ; C07K14/725 ; C07K16/30 ; A61K38/17 ; A61K45/06 ; C07K14/715 ; A61K48/00 ; A61K35/28 ; A61K39/00 ; A61K38/00
Abstract:
The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.
Public/Granted literature
- US20160096892A1 TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR Public/Granted day:2016-04-07
Information query
